Search
Now showing items 1-10 of 13
TB or not TB? Improving the understanding and diagnosis of tuberculosis through metabolomics
(Future Medicine, 2016)
“
...metabolomics has resulted in an exponential increase in the
number of newly identified tuberculosis biomarkers, which has not
only shed light on previously unknown disease mechanisms, but could
potentially ...
The application of metabolomics toward pulmonary tuberculosis research
(Elsevier, 2019)
In the quest to identify novel biomarkers for pulmonary tuberculosis (TB), high-throughput systems biology approaches such as metabolomics has become increasingly widespread. Such biomarkers have not only successfully been ...
Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin
(Elsevier, 2020)
Isoniazid and rifampicin are well-known anti-mycobacterial agents and are widely used to treat pulmonary tuberculosis (TB) as part of the combined therapy approach, recommended by the World Health Organization. The ingestion ...
Metabolomics biomarkers for tuberculosis diagnostics: current status and future objectives
(Future Medicine, 2017)
Numerous studies have contributed to our current understanding of the complex biology of pulmonary tuberculosis and subsequently provided solutions to its control or eradication. Metabolomics, a newcomer to the Omics ...
A metabolomics investigation of the function of the ESX-1 gene cluster in mycobacteria
(Elsevier, 2016)
The ESX-1 gene cluster, encoding the Type-VII secretion (T7S) system and its virulence associated proteins, ESAT-6 and CFP-10, is thought to be responsible for the transport of extracellular proteins across the hydrophobic ...
New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis
(Oxford Univ Press, 2016)
Objectives: Rifampicin is considered the most important antibiotic for treating TB, but unfortunately Mycobacterium tuberculosis is rapidly developing resistance to this drug. Despite the fervent research efforts to date, ...
A comparison of two extraction methods for differentiating and characterising various Mycobacterium species and Pseudomonas aeruginosa using GC-MS metabolomics
(Academic Journals, 2012)
We investigated the capacity of a metabolomics research approach to characterise and differentiate between various infectious Mycobacterium species and Pseudomonas aeruginosa, and compared two extraction procedures; 1) ...
A metabolomics approach to characterise and identify various Mycobacterium species
(Elsevier, 2012)
We investigated the potential use of gas chromatography mass spectrometry (GC–MS), in combination with multivariate statistical data processing, to build a model for the classification of various tuberculosis (TB) causing, ...
Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis
(Elsevier, 2018)
Over the past 5 years, there has been a renewed interest in finding new compounds with anti-TB action. Colistin methanesulfonate or polymyxin E, is a possible anti-TB drug candidate, which may in future be used either alone ...
Predicting tuberculosis treatment outcome using metabolomics
(Future Medicine, 2017)
Aim: Predicting a poor treatment outcome would offer significant benefits for patient care and for new drug development. Materials, methods & results: Urine samples from tuberculosis-positive patients with a successful and ...